Stock Analysis, Dividends, Split History

RARX / Ra Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price10.71
Volume252,800.00
Market Cap ($M)360.27
Enterprise Value ($M)259.39
Book Value ($M)94.92
Book Value / Share2.94
Price / Book3.73
NCAV ($M)87.53
NCAV / Share2.71
Price / NCAV4.02
Share Statistics
Common Stock Shares Outstanding 22,626,000
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 32,286,684
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.79
Return on Assets (ROA)-0.43
Return on Equity (ROE)-0.46
Balance Sheet (mrq) ($M)
Assets105.54
Liabilities10.62
Quick Ration/a
Current Ratio11.61
Income Statement (mra) ($M)
Revenues0.00
Operating Income-55.03
Net Income-54.44
Earnings Per Share Basic And Diluted-2.41
Cash Flow Statement (mra) ($M)
Cash From Operations-46.78
Cash from Investing-1.41
Cash from Financing-1.41
Identifiers and Descriptors
CUSIP74933V108
Central Index Key (CIK)1481512
Industry Groups

Split History

Stock splits are used by Ra Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?

2018-07-30 seekingalpha
Ra Pharma is developing RA101495, a C5 inhibitor and a potential competitor to Alexion's blockbuster Soliris. (7-0)

Insiders Are Bullish On Tiny Tonix (Again)

2018-07-24 seekingalpha
TNXP remains appropriate only for investors who can stomach the high risk in this potentially high-reward punt. (7-3)

Riding Ra Pharmaceuticals

2018-07-23 seekingalpha
Shares of Ra Pharmaceuticals (NASDAQ:RARX) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period. (8-0)

6 Speculative BioHealth Analyst Stocks That Could Rally 50% to 300%

2018-07-21 247wallst
The bull market is now more than nine years old. Many investors have begun looking for new ideas and new strategies to generate income and gains, and the old strategy of buying every major market selling day has become less rewarding in 2018 versus the prior few years. It turns out that Wall Street brokerages and research shops still have many stock picks for big upside. (55-11)

Top Analyst Upgrades and Downgrades: AEP, Facebook, Microsoft, PayPal, Philip Morris, Spotify, Under Armour and More

2018-07-20 247wallst
Stocks were indicated lower on Friday on more China woes, but it’s been a choppy time of late. The investing community has had less faith and has seen lower rewards from buying the dips in 2018 than in prior years. Many of those same investors also have been concerned about how they want their investments positioned ahead of the midterm elections, into international trade concerns and into 2019 and beyond. (49-2)

CUSIP: 74933V108